Molecular basis of resistance to proteasome inhibitors in hematological malignancies

Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a cornerstone position in the treatment of hematological malignancies, particularly multiple myeloma and mantle cell lymphoma, but also in experimental therapeutics of acute leukemia. However, the therapeutic eff...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Drug resistance updates Ročník 18; s. 18 - 35
Hlavní autoři:	Niewerth, Denise, Jansen, Gerrit, Assaraf, Yehuda G., Zweegman, Sonja, Kaspers, Gertjan J.L., Cloos, Jacqueline
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Scotland Elsevier Ltd 01.01.2015
Témata:	Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Boronic Acids - adverse effects Boronic Acids - pharmacology Bortezomib Drug Resistance, Neoplasm Hematologic Neoplasms - drug therapy Hematologic Neoplasms - pathology Hematology, Oncology and Palliative Medicine Humans Infectious Disease Leukemia Multiple myeloma Proteasome inhibitor Proteasome Inhibitors - pharmacology Pyrazines - adverse effects Pyrazines - pharmacology Resistance Resistance Bortezomib Proteasome inhibitor Leukemia Multiple myeloma
ISSN:	1368-7646, 1532-2084, 1532-2084
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!